This company has been acquired
Satsuma Pharmaceuticals Future Growth
Future criteria checks 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Satsuma Pharmaceuticals.
Key information
54.7%
Earnings growth rate
68.6%
EPS growth rate
Pharmaceuticals earnings growth | 21.5% |
Revenue growth rate | 60.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 19 May 2023 |
Recent future growth updates
Recent updates
Can Satsuma Pharmaceuticals (NASDAQ:STSA) Afford To Invest In Growth?
Feb 15Will Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?
Sep 02Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation
May 13Satsuma Pharmaceuticals: Sizing Up This One Trick Pony
Nov 07Satsuma shares surge on data from early-stage STS101 trial
Jun 16Do Institutions Own Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Shares?
Jan 26Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 11 | -20 | N/A | N/A | 4 |
12/31/2024 | 3 | -22 | N/A | N/A | 4 |
12/31/2023 | N/A | -25 | N/A | N/A | 4 |
3/31/2023 | N/A | -65 | -49 | -49 | N/A |
12/31/2022 | N/A | -70 | -52 | -52 | N/A |
9/30/2022 | N/A | -62 | -53 | -53 | N/A |
6/30/2022 | N/A | -61 | -50 | -49 | N/A |
3/31/2022 | N/A | -56 | -50 | -49 | N/A |
12/31/2021 | N/A | -51 | -45 | -43 | N/A |
9/30/2021 | N/A | -48 | -44 | -38 | N/A |
6/30/2021 | N/A | -47 | -45 | -39 | N/A |
3/31/2021 | N/A | -46 | -44 | -38 | N/A |
12/31/2020 | N/A | -48 | -47 | -42 | N/A |
9/30/2020 | N/A | -46 | -42 | -41 | N/A |
6/30/2020 | N/A | -42 | -42 | -42 | N/A |
3/31/2020 | N/A | -37 | -40 | -40 | N/A |
12/31/2019 | N/A | -28 | -30 | -30 | N/A |
9/30/2019 | N/A | -20 | -25 | -24 | N/A |
6/30/2019 | N/A | -13 | -15 | -14 | N/A |
3/31/2019 | N/A | -8 | -8 | -8 | N/A |
12/31/2018 | N/A | -7 | -7 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STSA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: STSA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: STSA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: STSA's revenue (60.3% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: STSA's revenue (60.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if STSA's Return on Equity is forecast to be high in 3 years time